Quantcast

Latest Multiple Myeloma Research Foundation Stories

2009-12-16 07:30:00

NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma...

2009-12-06 09:30:00

NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients. These data were presented today at the ASH/ASCO Joint Symposium at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. Enrollment in this trial is...

2009-12-02 17:10:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Multiple Myeloma Therapeutics - US Market Trends & Analysis http://www.reportlinker.com/p0164271/Multiple-Myeloma-Therapeutics---US-Market-Trends--Analysis.html Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been...

2009-11-12 08:00:00

Co-Pay Relief Program Provides Direct Financial Support for Pharmaceutical Co-Payments to Insured Patients in Medical and Financial Need WASHINGTON, Nov. 12 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is...

2009-10-05 13:38:14

Restoring their proper role holds promise for new approach to therapy Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor "“ to switch from defending the body against disease to shielding the myeloma cells from harm "“ Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell. The researchers found that immune-system cells known as plasmacytoid dendritic cells (pDCs) essentially assume a new...

2009-09-30 10:13:00

HACKENSACK, N.J., Sept. 30 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center today proudly announced the addition of David H. Vesole, M.D., Ph.D., F.A.C.P. to its Multiple Myeloma Division. He will join division chief David S. Siegel, M.D., Ph.D., who has built a world-renowned myeloma clinical and research practice at the Cancer Center. Dr. Vesole and Dr. Siegel are two of the foremost authorities in multiple myeloma, the second most prevalent form...

2009-08-13 12:39:45

The International Myeloma Foundation (IMF)"”supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians"”today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affect production of blood cells and can damage bone. Once considered a "rare disease of the...

2009-02-10 07:00:00

Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors. LOS ANGELES, Feb. 10 /PRNewswire-USNewswire/ -- IMBCR researchers uncovered a new way that cancers orchestrate the production of their own blood supply. Recent studies have shown that many tumors make a protein called pleiotrophin (PTN). They now show that PTN produced by tumor cells in multiple myeloma, a common form of bone...

2009-02-06 11:11:00

LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma and metastatic bone disease. Ethan Horwitz, Esq. is a partner in New York law firm of King & Spalding and has an extensive Intellectual Property practice. Mr. Horwitz has over 25 years of experience in the full range of...

2009-01-26 10:00:00

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA LOS ANGELES, Jan. 26 /PRNewswire-USNewswire/ -- IMBCR's "Cure Myeloma Project" is the nation's foremost effort to find a cure for multiple myeloma, a blood cancer that resides in bone marrow. Led by premier scientists in the world...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related